← 返回专利悬崖列表
CAS 1420478-87-0
benzyl (S)-2-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate
登记编号：ACAT-006
应用背景（按来源药适应症）
套细胞淋巴瘤阿可替尼慢性淋巴细胞白血病阿可替尼淋巴细胞性白血病阿可替尼
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 阿可替尼Acalabrutinib | Tier A · 立即攻坚 | 2030 |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
3-chloropyrazine-2-carbonitrile→(3-chloropyrazin-2-yl)methanamine hydrochloride→((benzyloxy)carbonyl)-L-proline→benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate→benzyl (S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate→benzyl (S)-2-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate→benzyl (S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate→N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide→benzyl (S)-2-(8-amino-1-(4-(pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate→(S)-4-(8-amino-3-(pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide→4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 2-Butynoic Acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 2-Butynoyl Chloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 3-Chloro-2-pyrazinemethanamine hydrochloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | (S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5 -a]pyrazin-3- yl)pyrrolidine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | [4-[(Pyridin-2-yl)carbamoyl]phenyl]boronic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 4-[8-Amino-3-(2S)-2-pyrrolidinylimidazo[1,5 -a]pyrazin-1-yl]-N-2- pyridinylbenzamide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。